The shadow of generic challenges has long loomed over copyright’s iconic drug, Viagra, sparking questions about the future of related drug holdings. While early years saw impressive profits, the exclusivity lapse has opened the path for less expensive substitutes, possibly lowering earnings and posing a real hazard for investors seeking secure i… Read More